A subpoenaed FDA criminal investigator has told Congress
that Aventis should have known that data it submitted to support the approval
of antibiotic Ketek was fraudulent. Agent Douglas Loveland testified that there
were so many “red flags” in one study that the company should have notified the
FDA.